RNS Number : 7698N MaxCyte, Inc. 01 October 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 October 2021 : MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company focused on providing enabling
RNS Number : 1652M MaxCyte, Inc. 17 September 2021 MaxCyte Set to Join Russell 2000® Index GAITHERSBURG, MD , September 16, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 6377L MaxCyte, Inc. 14 September 2021 MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2021 GAITHERSBURG, MD , September 13, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on
RNS Number : 6380L MaxCyte, Inc. 14 September 2021 MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections GAITHERSBURG, MD , September 13, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell
RNS Number : 8949K MaxCyte, Inc. 06 September 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Issue of Equity Increase to Block Listing Block Listing Return and Total Voting Rights GAITHERSBURG, MD , September 6, 2021 - MaxCyte, Inc.
RNS Number : 5833K MaxCyte, Inc. 02 September 2021 MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021 GAITHERSBURG, MD , September 02, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell
RNS Number : 0791I MaxCyte, Inc. 10 August 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options Gaithersburg, Maryland - 10 August 2021 : MaxCyte (Nasdaq: MXCT) (LSE: MXCT, MXCN) , a leading provider of cell-engineering
RNS Number : 9261H MaxCyte, Inc. 09 August 2021 MaxCyte Signs Clinical and Commercial License with Sana Biotechnology Agreement represents MaxCyte's 14 th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform in conjunction
RNS Number : 7572H MaxCyte, Inc. 05 August 2021 Amendments to Bylaws GAITHERSBURG, MD , August 5, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company "), a leading provider of cell-engineering platform technologies, announces that it has filed amended
RNS Number : 4604H MaxCyte, Inc. 03 August 2021 MaxCyte Announces Closing of Offering and Resulting Total Voting Rights This announcement contains inside information GAITHERSBURG, MD , August 3, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company
